Latest Omalizumab Stories
ZURICH, April 25, 2013 /PRNewswire/ -- - Phase 2b clinical trial of CYT003 in allergic asthma on-going as planned - Cytos' VLP platform is basis for a phase 1 clinical trial with an Anti-lgE Vaccine partnered with and conducted by Pfizer - Management team further strengthened - The Journal of Allergy and Clinical Immunology publishes phase 2a...
Surveyed Payers Expect to Restrict the Prescribing of Emerging Biologics Through Controls Similar to Xolair, Limiting Patient Access, According to a New Report from Decision Resources BURLINGTON, Mass., April 9, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that surveyed U.S. pulmonologists estimate that only 19 percent of their severe, refractory asthma patients are treated with...
Lawrence LeBlond for redOrbit.com - Your Universe Online Though not the most common occurrence, researchers do sometimes discover drugs marketed for one particular disease, disorder or illness can work well in treating a totally different condition. One recent discovery was that of a popular diabetes drug that showed promise in treating ovarian cancer. Another--not so recent--discovery was of the antidepressant drug Wellbutrin that proved to be effective in helping smokers kick the habit....
- Phase III study published in NEJM today and to be presented tomorrow met primary endpoint in moderate-to-severe chronic idiopathic urticaria (CIU) EAST HANOVER, N.J., Feb. 24, 2013 /PRNewswire/ -- Late-breaking results from ASTERIA II, a Phase III placebo-controlled study, showed positive results in patients with moderate to severe chronic idiopathic urticaria (CIU), referred to as chronic spontaneous urticaria (CSU) outside the United States, who remained symptomatic despite...
Data presented at the 2013 American Academy of Allergy, Asthma & Immunology Annual Meeting SAN ANTONIO, Feb. 23, 2013 /PRNewswire/ -- Boehringer Ingelheim presented today a new subset of data from the Phase III UniTinA-asthma(TM) program at the 2013 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting in San Antonio, Texas. In prespecified subgroups from two paired clinical trials, tiotropium delivered once daily via the Respimat® inhaler improved lung...
ZURICH, Feb. 4, 2013 /PRNewswire/ -- Cytos Biotechnology Ltd (SIX:CYTN) has been informed by Pfizer Inc. that the first patient has been dosed in a Phase 1 clinical trial with an anti-IgE vaccine, which is being developed under a license agreement between both parties. Pfizer's anti-IgE vaccine is based on Cytos' VLP ("virus-like-particle") vaccine platform. Christian Itin, Chairman and Chief Executive Officer of Cytos, comments: "We are very pleased that Pfizer has advanced its...
BURLINGAME, Calif., Sept. 18, 2012 /PRNewswire/ -- Igenica, Inc., a leading biopharmaceutical company focused on the discovery and development of first-in-class cancer antibody therapeutics, today announced the appointment of Mary Haak-Frendscho, Ph.D., to the role of Chief Executive Officer and member of the Board of Directors. Dr. Haak-Frendscho succeeds David Goeddel, Ph.D., who remains as Igenica's Chairman of the Board. Dr. Haak-Frendscho brings more than twenty years of...
INCLINE VILLAGE, Nev., July 11, 2011 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) announced a favorable ruling today, specifically, that on July 7, 2011, the Second Judicial District Court of Nevada ruled in favor of PDL on two motions to dismiss filed by Genentech and F. Hoffmann LaRoche, Ltd. (Roche) in PDL's lawsuit related to the 2003 settlement agreement with Genentech. The court denied Genentech and Roche's motion to dismiss four of PDL's five claims for relief and,...
Patients with severe allergic asthma that is inadequately controlled with the standard of care had improved symptoms and decreased flare-ups with injections of an antibody drug called omalizumab, according to experts at Baylor College of Medicine in a paper that appears in the current issue of Annals of Internal Medicine."Many patients suffering from asthma who are being treated with the recommended inhaled corticosteroids and long-acting beta agonists continue to have asthma...
SOUTH SAN FRANCISCO, Calif., May 6, 2011 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that the company will assume development of R343, its inhaled syk inhibitor for allergic asthma that recently completed several Phase 1 clinical trials. Pfizer Inc. is returning full rights to the R343 program as a result of its decision to exit the allergy and respiratory therapeutic area within R&D. Rigel is evaluating the details of R343's development to date and...
